Azar’s political play with drug importation
Editor’s Commentary: Why the HHS drug importation plan is a bad idea
The drug importation policy announced by Alex Azar last week is a political stunt, aimed at generating headlines at a time when the HHS secretary seems desperate to demonstrate to Donald Trump and the media that he’s fulfilling the president’s pledges to lower drug prices.
In fact, as Azar knows, importation will have a negligible effect on access to drugs.
Opening the door to importation as a price control tactic will, however, create precedents that will damage FDA, and consequently hurt biomedical innovators and patients.
The new policy would allow importation of